The U.S. Food and Drug Administration (FDA) has approved an expansion of pharmaceutical company Takeda's ALUNBRIG's current trial for lung cancer patients. ALUNBRIG is a selective next-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase-positive (ALK+) molecular alterations. It's designed for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer, icluding those with brain metastases. who were previously treated with crizotinib. Long-term results from the Phase 3 ALTA 1L trial showed ALUNBRIG as a superior first-line treatment. |https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line